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604Objective: Thoracic endovascular aortic repair (TEVAR) has become a widely established treatment for a vari-
ety of thoracic aortic pathologic diseases despite limited long-term data to support its use. We compared the
long-term outcomes of TEVAR with the 3 commercially available stents grafts for thoracic aortic aneurysms
to results in control subjects undergoing open surgery.
Methods: Demographic, clinical radiographic parameters were collected prospectively on patients enrolled in
trials assessing the Gore TAG (55), Medtronic Talent (36) and Cook TX2 (15) devices. Outcomes were com-
pared with 45 contemporaneous open controls. Detailed clinical and radiographic information was available
for analysis. Standard univariate, survival, and regression methods were used.
Results: During the study period (1995-2007) 106 patients were enrolled in TEVAR trials and there were 45
open controls. TEVAR patients were older and had significantly more comorbidities including diabetes and renal
failure. TEVAR patients had 2.3  1.3 devices implanted. Mortality (2.6% TEVAR, 6.7% open; P ¼ .1),
paralysis/paraparesis (3.9% TEVAR, 7.1% open; P ¼ .2), and prolonged intubation more than 24 hours (9%
TEVAR, 24% open; P ¼ .02) tended to be more common in the open controls. Overall survival at 10 years
was similar between groups (log rank P ¼ .5). Multivariate predictors of late mortality included age, chronic
obstructive pulmonary disease, diabetes, and chronic renal failure. Use of TEVAR versus open surgery did
not influence mortality (hazard ratio, 0.9 95% confidence interval, 0.4-1.6). Over 5 years of radiographic
follow-up in the TEVAR group, mean aortic diameter decreased from 61 to 55mm. Freedom from reintervention
on the treated segment was 85% in TEVAR patients at 10 years.
Conclusions: TEVAR is a safe and effective procedure to treat thoracic aortic aneurysms with improved peri-
operative and similar long-term results as open thoracic aortic repair. TEVAR-treated aneurysm diameters ini-
tially decrease and then stabilize over time. (J Thorac Cardiovasc Surg 2012;144:604-11)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Cardiovascular Surgaortic stent grafts have shown significantly improved early
quality of life versus open surgery and have generally
shown a trend toward better perioperative survival and free-
dom from major complications.1-4 The original Food and
Drug Administration Investigational Device Exemption
(FDA IDE) studies that led to approval of the currently
available devices, including the Gore TAG (W. L. Gore &
Associates, Inc, Flagstaff, Ariz), Medtronic Talent
(Medtronic, Inc, Minneapolis, Minn), and Cook Zenith
TX2 stent grafts (Cook Endovascular, Bloomington, Ind),
specifically looked at patients with favorable anatomy in
descending thoracic aortic aneurysms.5-7 The early results
in these trials were highly favorable toward stent grafts.
However, little is known about the long-term fate of tho-
racic aneurysms treated by TEVAR. The purpose of this in-
vestigation is to determine the long-term survival and
freedom from aortic complications in patients enrolled in
5 FDA IDE studies of TEVAR grafts from a single center
and compare them with a group of open control patients
with similar anatomic features.ery c September 2012
Abbreviations and Acronyms
FDA ¼ Food and Drug Administration
IDE ¼ Investigational Device Exemption
TEVAR ¼ thoracic endovascular aortic repair
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Patients
All patients enrolled at the Hospital of the University of Pennsylvania in
the Gore 99-01 (14 patients), Gore 03-03 (10 patients), Gore 04-02 (16 pa-
tients), Medtronic Talent (33 patients), Cook TX2 (14 patients), and Gore
05-02 (13 patients) clinical trials were included in the study. A comparator
group of 45 open cases with descending thoracic aortic aneurysms in
a fairly contemporary period was identified from a total of 204 open tho-
racic/thoracoabdominal aortic cases. The patients selected in the open con-
trol group had anatomy that was amenable to TEVAR with a proximal and
distal neck of at least 2 cm with maximal neck diameters that could be
treated by available TEVAR devices and did not have excessive angulation
or tapering. Some of the controls (6/45) were not amenable to crossclamp-
ing proximally owing to friability or calcification and the operations were
performed under circulatory arrest conditions with an open anastomosis.
Reverse hemiarch type anastomoses were excluded. Only aneurysmal dis-
ease was included.
Surgical Techniques
TEVAR at the Hospital of the University of Pennsylvania is performed
by a multidisciplinary team including cardiovascular surgery, vascular sur-
gery, cardiovascular anesthesia, neurology, and diagnostic radiology. The
majority of cases were performed in a dedicated hybrid operating room
able to accommodate with a fixed high-quality floor-mounted image inten-
sifier, transesophageal echocardiography equipment, intravascular ultra-
sound, neuromonitoring equipment and a cardiopulmonary bypass pump
if necessary, and multiple movable viewing screens that can display angi-
ography, hemodynamics, transesophageal echocardiography, and intravas-
cular ultrasound simultaneously.8
A fairly liberal approach to retroperitoneal access is used in cases of
marginal femoral access, which generally occurred in vessels that were
small, heavily circumferentially calcified, or extremely tortuous. In in-
stances of planned left subclavian artery coverage, prophylactic left com-
mon carotid artery–left subclavian artery bypass is performed
perioperatively. Coiling of the left subclavian artery from the ipsilateral
brachial artery is routine in cases of left common carotid artery–left subcla-
vian artery bypass at the time of stent insertion.9
Open cases were done generally with left atrial–left femoral artery par-
tial bypass (2-3 L flow) maintaining proximal mean perfusion pressures of
90 to 100 mm Hg and distal mean pressures of 70 to 80 mm Hg. Sequential
clamping was performed to minimize ischemic times. Large viable inter-
costals arteries were preserved either by beveling the distal anastomosis
or by selective reimplantation. Circulatory arrest cases were performed us-
ing electroencephalography and somatosensory evoked potential monitor-
ing. In circulatory arrest cases, bypass was initiated via the femoral artery
and vein and a left ventricular vent was placed via the left inferior pulmo-
nary vein or apex. Patients were cooled to electroencephalographic silence
or 18C, and total body retrograde perfusion was performed to keep the
vasculature deaired.10
Neuroprotective Strategies
Use of somatosensory evoked potential monitoring was not standard-
ized in this population but evolved into a routine with increasing experi-
ence. Preoperative spinal drains were used in all patients who wereThe Journal of Thoracic and Caconsidered at high risk for spinal ischemia including those with previous
abdominal aortic aneurysm repair, descending thoracic aortic surgery, or
planned complete aortic coverage from the left subclavian to the celiac
axis. Descending thoracic aortic coverage was classified according to the
method proposed by Safi11: type A, left subclavian artery to midthoracic
aorta (T6); type B, midthoracic aorta (T6) to celiac axis; or type C, left sub-
clavian to celiac axis. The protocol for management of spinal cord ischemia
in the postoperative period included spinal drainage to cerebrospinal fluid
pressure below 10 cm H2O and aggressive blood pressure augmentation
with mean arterial pressures over 90 mm Hg.12
Data, Statistical Methods, and Follow-up
Perioperative data were abstracted from the Penn Thoracic Aortic Data-
base, a prospectively maintained database containing detailed demo-
graphic, operative, and device information. Long-term follow-up was
performed on an annual basis for at least 5 years in the TEVAR patients
as part of the various trial protocols with clinical follow-up and computed
tomographic scans. Telephone clinical assessments and outpatient clinic
records were also abstracted for open control and TEVAR patients.
Follow-up was 95% complete at a minimum of 3 years. Median follow-
up interval was 66 months (interquartile range, 32 to 79 months) in TEVAR
and 91 months (interquartile range, 29 to 123 months) for open control pa-
tients. Late aortic reinterventions were characterized according to whether
they involved the previously treated segment of aorta including proximal
and distal landing zones or an unrelated segment such as the infrarenal
aorta or a de novo ascending aneurysm.
Early outcomes were compared using standard univariate statistics in-
cluding the Student t test for continuous data and Fisher’s exact test for cat-
egorical data. Multivariate analyses for predictors of operative mortality
were determined using logistic regression. All variables deemed clinically
relevant were maintained in the model and no automated selection proce-
dures were used. Late survivals were analyzed using the Kaplan-Meier sur-
vival technique, and multivariate predictors of late survival were determined
using Cox proportional hazards modeling. Late survival data were deter-
mined using a linkage to the national Social Security Death Index. The study
protocol was approved by the local institutional review board.
RESULTS
Between 1999 and 2007, we enrolled 106 patients in the 5
FDA IDE studies. Open controls were chosen on the basis of
anatomic characteristics in the period between1994 and 2004
(Figure 1). TEVAR patients were significantly older (74.3
91years vs 69.5 11.1 years;P¼ .006) and had a higher pro-
portion of diabetes and renal failure than open control pa-
tients. Demographic information is presented in Table 1.
Open control procedures were predominantly performed
on left atrial–femoral artery bypass (39/45, 86%) with the
remaining 6 (14%) being performed on circulatory arrest.
Mean bypass time was 84  41 minutes and crossclamp
time was 55  20 minutes. In circulatory arrest cases,
mean arrest time was 36  8.5 minutes (Table 2).
Among open control patients, 16 (35.6%) underwent Safi
type A aortic replacement, 2 (4.4%) underwent type B re-
placement, and 27 (60%) underwent type C replacement.
Preoperative spinal drains were placed in 36/45 (80%) of
open cases. Among TEVAR patients, 38 (36%) underwent
type A aortic coverage, 28 (26%) underwent type B cover-
age, and 40 (38%) underwent type C coverage. Preopera-
tive spinal drains were placed in 49 (47%) of 106
TEVAR cases.rdiovascular Surgery c Volume 144, Number 3 605
FIGURE 1. Distribution of open and thoracic endovascular aortic repair
(TEVAR) cases in the study over time.
TABLE 2. Operative characteristics
Operative data
TEVAR (n ¼ 106)
No. of devices implanted
 Gore TAG (n ¼ 55)
 Medtronic Talent (n ¼ 36)
 Cook TX2 (n ¼ 15)
2.3  1.3
1.9  0.9
3.2  1.5
1.8  0.8
Preop left carotid–subclavian bypass 18 (16.9%)
Access complication
 Iliofemoral dissection/tear
 Stent
 Open repair/bypass
 Local femoral repair/thrombectomy/
endarterectomy
18 (16.9%)
4 (3.7%)
8 (7.5%)
8 (7.5%)
Open cases (n ¼ 45)
Perfusion
Partial left heart bypass 39 (86%)
Full bypass with circulatory arrest 6 (14%)
Crossclamp time (min) 55  20
Cardiopulmonary bypass time (min) 84  41
Circulatory arrest time (min) 36  8.5
TEVAR, Thoracic endovascular aortic repair.
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DAmong TEVAR patients, 18 of 106, all in the type A or C
coverage group, underwent preoperative carotid subclavian
bypass with anticipated coverage of the origin of the left
subclavian artery. There were 4 cases of subclavian cover-
age without previous bypass. The mean number of stents
implanted were 1.9  0.9 for the Gore TAG, 3.2  1.5 for
the Medtronic Talent, and 1.8  0.8 for Cook Zenith
TX2. There were 18 (16.9%) access complications
including 4 managed with an iliac artery stent, 8 managed
with an open repair or bypass of the iliac artery, and 8 man-
aged with local femoral artery repair, thrombectomy, or
endarterectomy.
Overall, 30-day mortality was 2.8% for TEVAR and
6.7% for open control patients (P ¼ .4), and in-hospital
mortality was 2.8% for TEVAR and 8.9% for open control
patients (P ¼ .1). Paraparesis or permanent paralysis oc-
curred in 3.8% of TEVAR and 6.7% of open patients
(P ¼ .4), whereas permanent paralysis occurred in 1.9%
of TEVAR and 4.4% of open patients, respectivelyTABLE 1. Preoperative characteristics
Feature
TEVAR,
N (%)
Open controls,
N (%) P value
N 106 45
Age 74.3  9.1 69.5  11.1 .006
Female 46 (43%) 27 (60%) .07
Smoking 82 (77%) 40 (89%) .1
COPD 41 (39%) 24 (53%) .1
Prior CVA 9 (9%) 7 (16%) .2
Hypertension 94 (88%) 40 (89%) .7
Previous MI 20 (19%) 9 (20%) .4
Previous CABG 16 (15%) 7 (16%) .9
Diabetes 22 (21%) 3 (6.7%) .03
Renal failure 11 (10%) 1 (2.2%) .04
Acute presentation 9 (9%) 7 (16%) .4
TEVAR, Thoracic endovascular aortic repair; COPD, chronic obstructive pulmonary
disease; CVA, cerebrovascular accident; MI, myocardial infarction; CABG, coronary
artery bypass grafting.
606 The Journal of Thoracic and Cardiovascular Surg(P ¼ .6). Stroke or transient ischemic attack occurred in
4.7% of TEVAR patients and 6.7% of open patients
(P ¼ .6). Permanent stroke occurred in 1.9% of TEVAR
patients and 2.2% of open patients (P ¼ .7). Prolonged in-
tubation for more than 24 hours occurred in 10% of TEVAR
and 22% of open patients (P ¼ .06). Overall, 10% of
TEVAR patients and 31% of open patients experienced
death, permanent stroke, paralysis, or prolonged assisted
ventilation (P ¼ .003). There were no instances of arm
ischemia requiring treatment and all 4 patients with un-
planned left subclavian artery coverage had no postopera-
tive neurologic sequelae (Table 3).
Overall survival at 8 to 10yearswas similar betweengroups
(log rank P ¼ .5) (Figure 2). Multivariate predictors of late
mortality included age, chronic obstructive pulmonary dis-
ease, and chronic renal failure (Table 4).UseofTEVARversus
open surgery did not influence latemortality in a risk-adjustedTABLE 3. Perioperative results
Post-operative
characteristics
TEVAR
(N ¼ 106)
Open controls
(N ¼ 45)
P
value
Thirty-day mortality 3 (2.8%) 3 (6.7%) .4
Hospital mortality 3 (2.8%) 4 (8.9%) .1
Paralysis/paraparesis 4 (3.8%) 3 (6.7%) .4
Permanent paralysis 2 (1.9%) 2 (4.4%) .6
Stroke/transient ischemic
attack
5 (4.7%) 3 (6.7%) .6
Permanent stroke 2 (1.9%) 1 (2.2%) .7
Prolonged intubation (>24 h) 10 (9.6%) 10 (22%) .06
Composite
(death, paralysis, permanent
stroke, intubation>24 h)
11 (10%) 14 (31%) .003
TEVAR, Thoracic endovascular aortic repair.
ery c September 2012
FIGURE 2. Long-term survival. TEVAR, Thoracic endovascular aortic repair.
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DCox proportional hazards regression model (hazard ratio, .9;
95% confidence interval, 0.8-1.6).Women had better survival
than men in long-term follow-up (hazard ratio, 0.6; 95% con-
fidence interval, 0.5-0.9), but this effect was only seen in the
open group (gender $ group interaction; P ¼ .01).
There were 19 aortic reinterventions in the treated seg-
ments in the TEVAR group in 14 patients. One retrograde
type A aortic dissection was found in imaging 3 months
after index TEVAR, and 1 retrograde type A dissection
was found after a reintervention with a proximal exten-
sion. Both retrograde type A dissections were treated
with open arch repair with 1 perioperative mortality.
Three other open reinterventions were needed for failure
to achieve adequate seal in the treated segment (type I en-
doleak). There were 14 endovascular reinterventions on
the treated segment including 11 for type I endoleaks
and 3 type 3 endoleaks. Overall freedom from reinterven-
tion on the treated segment was 85.7%  3.6% in TE-
VAR patients at 8 years (Figure 3) There were no
treated segment reinterventions in the open group (log
rank P ¼ .02 for TEVAR vs open comparison). ThereTABLE 4. Predictors of late mortality (Cox proportional hazards
regression)
Characteristic Hazard ratio 95% CI
Age 1.1 1.0-1.2
Female* 0.6 0.5-0.9
Hypertension 1.6 0.7-3.5
Diabetes 1.1 0.7-2.3
CAD 1.3 0.8-1.8
Cerebrovascular disease 1.2 0.7-1.2
COPD 1.9 1.1-2.7
Chronic renal failure 1.7 1.1-2.6
TEVAR vs open 0.9 0.8-1.6
CI, Confidence interval; CAD, coronary artery disease; COPD, chronic obstructive
pulmonary disease; TEVAR, thoracic endovascular aortic repair. *Gender group inter-
action, P ¼ .01.
The Journal of Thoracic and Cawere 9 late unrelated aortic interventions in the TEVAR
group including 7 infrarenal aorta or iliac artery and 2 as-
cending aorta. There was 1 infrarenal and 1 ascending
aortic intervention in the open group. Over 5 years of ra-
diographic follow-up in the TEVAR group, mean aortic
diameter decreased 5.7  10.3 mm from 61.0  9.9
mm to 55.3  13.4 mm (P ¼ .01) (Figure 4). Over the
5-year period, 60.3% of patients had regression of aortic
diameters, 7.5% had an increase of greater than 5 mm,
and the remainder had no change.
DISCUSSION
Traditional open repair of the thoracic aorta is tradition-
ally associated with significant permanent neurologic mor-
bidity and mortality. In recent series from high-volume
centers of excellence, mortality and neurologic morbidity
rates range from 5.4% to 7.2% for mortality, 2.1% to
6.2% for permanent stroke, 5.7% for permanent parapare-
sis, and 0.8% to 2.3% for permanent paralysis, respec-
tively.13,14 In the multicenter open control groups for the
Gore TAG, Medtronic Talent, and Cook Zenith TX2 stent
grafts, mortality and neurologic morbidity rates range
from 5.7% to 11.7% for mortality, 4.3% to 8.6% for
permanent stroke, 5.7% for permanent paraparesis, and
3.4% to 8.5% for permanent paralysis, respectively.5-7 In
reference to these findings, mortality and morbidity in our
open control group were comparable at 6.7% mortality,
2.2% stroke, 2.2% permanent paraperesis, and 4.4%
permanent paralysis.
Similarly, the perioperative results for the 3 stent graft trials
in theTEVARarms showed1.9% to 2.1% formortality, 2.4%
to 4% for stroke, 4.4% to 7.2% for permanent paraparesis,
and 1.3% to 3% for permanent paralysis, respectively.5-7
Again, our results were similar with 2.8% mortality, 1.9%
for stroke, 1.9% for permanent paraparesis, and 1.9% for
permanent paralysis, respectively.5-7rdiovascular Surgery c Volume 144, Number 3 607
FIGURE 3. Freedom from treated aortic segment reintervention. TEVAR, Thoracic endovascular aortic repair.
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DAlthough the use of TEVARhas proliferated rapidly, long-
term data regarding the efficacy of this procedure to prevent
premature death are absent. Extrapolating on data from
abdominal stent-grafting studies in which there was no
long-term survival benefit for intervention versus medical
therapy,15 some authors have proposed that TEVAR does
not change the natural history of the disease, and, although
less invasive, may be inferior to open therapies.16 The key
finding of this study is that over a 5- to 10-year horizon, TE-
VAR patients clearly had more reinterventions than open
control patients but had identical all-cause mortality. Given
the dramatically older age of the TEVARpatients, we had ex-
pected a higher unadjusted mortality in the TEVAR group
and our results indicate that surgeons can safely apply this
strategy. This finding also demonstrates the importance of re-
peat surveillance imaging in TEVAR patients and a rigorousFIGURE 4. Change in aortic dimensions over time in thoracic endovascu-
lar aortic repair (TEVAR) patients.
608 The Journal of Thoracic and Cardiovascular Surgapproach to reintervention in cases in which there is progres-
sion. The overall decline in aneurysm size appeared to be du-
rable, although we only had detailed imaging information at
5 years in a small group of patients.
In this series, many of the open patients between 2001
and 2003 were initially evaluated to be enrolled in the
Gore TAG 99-02 trial for TEVAR, but this trial was halted
to redesign the Gore TAG stent graft owing to spine frac-
tures. As a result, these patients no longer had access to
an endovascular device and were treated with open surgery.
In our series, we had 1 incidence of stent spine fracture in
a well-sealed aneurysm that did not require any further
reintervention.
In the overall series, 9.4% of patients had a significant
access issue requiring more than a local femoral artery re-
pair and a further 7.5% required simple local femoral end-
arterectomy and/or thrombectomy. Access complications
were fairly frequent in the earliest patients in the series
and with increased experience and optimal device selection
have become uncommon. Our analysis of a larger group of
TEVAR patients showed a distinct diminishment in access
complications over time.
Since the first implants of ‘home-made’ grafts con-
structed on the back table, TEVAR devices have become
smaller, more flexible, have improved device conformabil-
ity, less porosity, and more sizing options.17-19 Many of the
cases in this series were our institutional first experiences
with TEVAR grafts, and over time our experience has
guided our practice toward improved clinical case
planning and outcomes. Evolution of the multidisciplinary
TEVAR team to include cardiac and vascular surgeons,
cardiovascular anesthesia, diagnostic radiology, and
neurologists has enabled application of this technology to
sicker patients while maintaining outcomes.20ery c September 2012
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DStudy Limitations
The current study, while controlled using anatomic inclu-
sion criteria, is not randomized and therefore subject to se-
lection, measurement, and attribution biases. Small sample
sizes, although similar to those of the multicenter pivotal
FDA studies for these stent grafts, further limit the overall
generalizability of the results and our ability to perform
complex risk adjustment. Further, this study is from a single
center highly experienced in this procedure, andmulticenter
data would bemore generalizable. Our use of all-cause mor-
tality instead of aorta-related mortality was due to the lon-
gitudinal retrospective nature of the study. As such, we did
not have detailed specific information about the exact cause
of death in some patients to delineate aortic deaths from
other causes. We propose that the all-cause mortality out-
come we used in this study is the most stringent and appro-
priate for aortic patients inasmuch as sudden death is
a frequent end point from aortic rupture and is not subject
to attribution biases.SUMMARY
Among the patients in this study, TEVAR was both safe
and effective in the short and long term to treat thoracic aor-
tic aneurysms and offered similar survival to open therapies.
TEVAR patients did require repeat interventions more fre-
quently, although the vast majority of these are performed
by an endovascular approach. Aneurysm dimensions appear
to decrease maximally in the first year and remain stable
from that point onward. Further follow-up of these patients
is planned and larger multicentric studies will provide fur-
ther confirmation of these findings.References
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Dr John S. Ikonomidis (Charleston, SC). I have no relation-
ships to disclose that are relevant to this discussion. Nimesh, I en-
joyed your presentation very much. We clearly need more data
with regard to long-term outcomes in these patients.
I would like to raise a few issues related to your patient groups.
First, with the control open group, I am a little puzzled by your
choice to include 6 patients who had hypothermic circulatory ar-
rest. Why did you choose to enter those patients into this analysis
when, clearly, circulatory arrest is not used in the stent graft group,
and we know frommany studies that the use of circulatory arrest in
aortic surgery, especially longer times, is itself a predictor of neu-
rologic outcome and even mortality? The second part of that ques-
tion is, what happens to the control group if you eliminate those 6
patients?
Dr Desai. Thank you for the question. Our inclusion was based
on defined anatomic substrates. If a patient had an adequate zone 2
landing zone, he or she was considered appropriate to include in
the study. Not all patients with zone 2 landing zones cannot neces-
sarily undergo crossclamping. In this case, when the operative re-
ports were reviewed, the reasons for not clamping the aorta in that
region were aortic calcification or mobile atheroma. By compari-
son, the TEVAR IDE studies, particularly the VALOR trial (Vascu-
lar Talent Thoracic Stent Graft System for the Treatment of
Thoracic Aortic Aneurysms) for the Talent device, 40% of the pa-
tients in that group had bare metal going into zone 2 or even zone 1.
These are patients who can be treated with TEVAR, but if the op-
erations are done open they may require circulatory arrest. Theyrdiovascular Surgery c Volume 144, Number 3 609
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patients who could not be treated with TEVAR.
To answer your other question about what happens if we remove
these patients from the group:We had 1 mortality in that group and
1 stroke. The numbers are too small to really parse out those kinds
of details, and the overall objective of the study was to look at the
long-term not short-term outcomes; however, they would make the
open controls seem slightly better in the perioperative period. I be-
lieve it is more fair to go by anatomy as we did in this article, be-
cause these are people in whom we could have used a stent.
Dr Ikonomidis. While I understand that the main purpose of
this study was to assess long-term outcome, nevertheless I am in-
terested in some of the short-term information on these patients.
For example, I noticed that you had 38 patients in the TEVAR
group that had so-called A anatomy. From the diagram that you
showed, it looks as though aneurysms in this group originate
very close to the left subclavian to the point that one would pre-
sume that those patients had their left subclavian covered as part
of their procedure. Is that correct?
Dr Desai.As this was so early in our experience and these were
trial patients, we did not challenge into the arch with the TEVAR
graft as much as we would today. Many were very isolated aneu-
rysms in the proximal thoracic aorta and had a reasonable landing
zone between the aneurysm and the takeoff of the subclavian. We
may have flared into the left subclavian or put bare metal into it but
not actually covered it.
There were only 4 patients who had unplanned, that is, no pre-
operative left carotid–subclavian bypass, coverage of the left sub-
clavian, and we did not have any neurologic sequelae or arm
ischemia in those patients.
Dr Ikonomidis. What about cerebrospinal fluid drains? I no-
ticed that in the open group about 80% of patients got cerebrospi-
nal fluid drains in contrast to the TEVAR group, in which 40% got
drains. How did your neurologic complication rates distribute be-
tween those groups? Do you think that you could modify your re-
sults in the TEVAR group by more aggressive use of cerebrospinal
fluid drains? Has your strategy changed?
Dr Desai.Our strategy has not changed. The TEVAR group had
less type C coverage, so in general there was less aorta covered and
fewer intercostals disrupted. This explains most of the difference
in the rate of placement of drains. There are other factors on which
I did not elaborate here, including previous ascending aortic aneu-
rysm repair, which influence our use of drains as well. Again, we
are only looking at 4 or 5 incidents of paralysis within the whole
group, including both cohorts. It is impossible to parse out those
details.
Our protocol is that we place a drain for type C coverage and
any other previous aortic intervention in the abdominal aorta.
Dr Ikonomidis. The last issue I wanted to bring up was the ilio-
femoral arterial access complication rate. Almost 1 in 5 patients in
the TEVAR group had some sort of iliofemoral arterial access
complication. I presume all of these were not ‘‘femoral artery or
iliac artery on a stick’’ type complications. Nevertheless, it seems
to me that this rate is a bit high. Was this part of a learning curve in
the way you evaluated your patients? Did you see these complica-
tions evenly distributed over the time period? Have you modified
the way you assess your patients preoperatively in terms of your
strategy for TEVAR as a result of this?610 The Journal of Thoracic and Cardiovascular SurgDr Desai. We have definitely become more liberal with retro-
peritoneal access and also have more devices to choose from,
some of which have smaller profiles and are more flexible. There
is definitely a learning curve component. When we presented our
larger series of 500 TEVARs at the Western Thoracic in 2009,
we showed that the incidence of access complications between
the first 250 stent grafts we did and the second had been cut
in half dramatically, and they have become extremely uncom-
mon with the preoperative planning and our approach to access
in the current era. Similarly, actually, postoperative or perioper-
ative spinal ischemia in our TEVAR patients has virtually disap-
peared as an entity, and it goes beyond just putting in a drain but
also hemodynamic management approaches that we have
adopted.
Dr D. Craig Miller (Stanford, Calif). I am looking around for
Alberto Pochettino, Joe Bavaria, or Wilson Szeto, because I am
not sure it is fair to ask Nimesh some pretty tough questions. I
am afraid you will feel like John Ikonomidis just softening
you up.
You have a problem with small numbers of patients and a rela-
tively small number of adverse events in both groups, as you al-
ready have admitted; therefore, how can you really draw any
broad inferences? You also did not take full statistical advantage
of this retroelective analysis, despite matching for the patients’
anatomy. Wouldn’t this be a beautiful place to use propensity
score analysis to neutralize for the effects of confounding inde-
pendent variables? You will unbalance the numbers, but at least
you are going to have a more apples-to-apples comparison. I do
not think our standard level of clinical research reporting today
can allow retrospective comparative observations to be presented
without adjusting as much as possible for known confounders.
However, the numbers are small and may not be sufficient to gen-
erate a stable propensity model. We really need a rigorous multi-
center collaborative approach with larger patient numbers to
answer the important questions you are asking. Admittedly, we
all are guilty of cluttering the literature with our own relatively
small single-center reports, but we must figure out ways to do
better.
Second, I amafraid your conclusion slide should be redone.Your
data do not substantiate the conclusion about less morbidity with
TEVAR. The only odds ratio that was significant was the interac-
tion for women in the open group. All of the other odds ratios
crossed 1.0. How can you really conclude there is less morbidity
with TEVAR?
Dr Desai. Just to answer your first question about multivariate
adjustment, when we ran propensity matching, we encountered is-
sues with data loss.
Dr Miller. There weren’t enough comparable patients?
Dr Desai. There was a paucity of matched pairs. The Cox pro-
portional hazard model that I presented provides a similar risk ad-
justment, although not as visually elegant or easy to understand as
propensity matching. It is full multivariate risk with similar fidelity
to propensity adjustment.
In terms of morbidity issues, we showed in the perioperative pe-
riod that prolonged ventilation was statistically significantly more
common in open patients. The other complications also tended to
be higher in open patients, and in a larger sample that difference
may or may not be significant.ery c September 2012
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is likely to be significant in a larger series. I think you would be
hard pressed to show major differences, even in a fairly large trial,
in terms of mortality, spinal complications, or stroke with contem-
porary management of the open and TEVAR cases.
DrMiller.We have to go back and look at those odds ratios and
see which ones cross 1.0. This may look like the EVEREST-II trial
(Endovascular Valve Edge-to-Repair Study): It looks great on the
surface, but digging deeper reveals it is only due to differences in
transfusions and ventilator time. My point is that I am concerned
you are overstating your conclusions.
You mentioned on that slide that historical paraparesis/paraple-
gia rates after open surgical graft replacement were all 2% to 8%. It
should be noted that the first report on the list from Joe Coselli’s
group had a rate of 0.8%.
Dr Desai. That was 0.8% for permanent total flaccid paralysis,
and it was another 5.7% for permanent paraparesis, which has
a pretty broad definition.
Dr Miller. Fair enough. It also is an adverse event defined sub-
jectively and differently around the world. My current hobbyhorse
is voicing concern that the entire thoracic field is being ‘‘dumbed
down’’ as the TEVAR era (which we at Stanford started 19 years
ago in 1992) evolves, in no small part owing to studies similar to
yours in which the rule of ‘‘noninferiority’’ is taken as gospel.
Even centers that used to know how to do open thoracic aortic sur-
gery with reasonable results are losing those skills over time. We
need to remind ourselves that the jury is still out regarding long-
term durability, reintervention rates, and survival after TEVAR
compared with after open graft replacement.
DrMarcR.Moon (St Louis,Mo).Didyourgrowth slide show that
some of the aneurysmswent from 4 cm up to 7 or 8 cm on follow-up?
Dr Desai. In a couple of cases, yes.
Dr Moon. What was going on there?
Dr Desai. A couple of those were converted to open. One of the
lessons inourearly experiencewithTEVARis, ifyouhaveaproximal
type I endoleak, it can evoke an unstable situation. Those aneurysms
often will grow very quickly and possibly more quickly than if you
had left them alone. You are mandated to reintervene either by put-
ting a stent in and getting a proximal seal or reoperating on that pa-
tient in an open fashion. There is definitely a group of patients whose
aortas will dilate out very quickly if you do not get a proximal seal.The Journal of Thoracic and CaDr Moon. Were you replacing 4-cm aortas? What was the
cutoff?
Dr Desai. Smaller sizes were seen in saccular aneurysm with
rapid expansion.
Dr Pochettino. I would like to respond to Dr Miller’s comment
Inasmuch as I did most of the open procedures. I was actually sur-
prised at how good the outcomes of open thoracic replacement
were. That occurred despite the fact that the majority of the
open operations were done via thoracotomy when the patients be-
came unstable. The reality of the trial was that the stent grafts were
not readily available, and a minimum of 6 to 8 weeks was neces-
sary to design the endovascular repair and obtain the needed de-
vices from the manufacturers. If the patients were stable for 6 to
8 weeks for the stent to be manufactured and shipped over, they
would undergo endovascular therapy. There was an intrinsic bias
of most of the patients having open surgery being relatively unsta-
ble with some of them being on the verge of aortic rupture. Despite
that, the outcomes of open thoracic replacement were quite good.
Nearly all of the open repair patients wewould treat today with en-
dovascular techniques.
In principle, I agree with the need for a large multi-institutional
randomized study of open versus endovascular treatment of tho-
racic aortic aneurysm. However, with present technology, in to-
day’s world, it has become impossible to randomize between
open and stent grafts. No patient would be willing to enter that
study. A priori, I do not have the insight to know what is best for
them, although deep down I have some opinions I could share
with the patients. The opportunity to perform that large random-
ized study has escaped us and I do not think it is ever going to
be made in today’s world.
Dr Desai. If I can summarize, there certainly is a feeling by
some in the literature that putting a stent graft in an aorta does
not change the natural history of the aneurysmal disease, and
that EVARs or TEVARs do not prolong people’s lives the way
that open surgery does. What we tried to show in this article was
that whether you had an open operation or a TEVAR, within the
limitations of the data we have discussed, your survival was sim-
ilar. We do not have a true control group of patients who did not
get operated on, but being operated on in an open fashion or having
a TEVAR led to the same outcome, and the patient can choose
which procedure he or she wants.rdiovascular Surgery c Volume 144, Number 3 611
